Lung Cancer | Specialty

DS-1062 Elicits Intriguing Early-Phase Data in Advanced NSCLC

September 12th 2019

The investigational Trop-2–targeting antibody-drug conjugate DS-1062 demonstrated antitumor activity in unselected patients with unresectable, advanced non–small cell lung cancer.

Atezolizumab Monotherapy Improves Survival in Frontline PD-L1-High NSCLC

September 12th 2019

Single-agent atezolizumab extended overall survival compared with chemotherapy as a frontline treatment for patients with advanced nonsquamous and squamous non–small cell lung cancer and high PD-L1 expression, according to topline findings from the phase III IMpower110 trial.

FDA Grants Tepotinib Breakthrough Designation for METex14-Altered NSCLC

September 11th 2019

The FDA has granted a breakthrough therapy designation to the MET inhibitor tepotinib as a treatment for certain patients with metastatic non–small cell lung cancer with MET exon14-skipping alterations.

Dr. Campelo on the Rationale for the ALTA-1L Trial

September 11th 2019

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC

September 11th 2019

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

Mutation-Defined Lung Cancer Trial Yields Hits and Misses for Targeted Therapy

September 11th 2019

Targeted therapies for non­–small cell lung cancer produced mixed results in a novel multiarm clinical trial that matched tumor mutations to drugs targeting the mutations.

Atezolizumab Combo Shows Clinical OS Benefit in PD-L1-High Squamous NSCLC

September 10th 2019

The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer.

Dr. Drilon on Results of the Phase I/II LIBRETTO-001 Trial

September 10th 2019

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

Larotrectinib Is Highly Active in Patients With NTRK Fusion+ NSCLC

September 10th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine, Harvard Medical School, discusses the updated activity of larotrectinib in NTRK fusion–positive lung cancer.

Selpercatinib Achieves High Response Rate in RET+ NSCLC

September 10th 2019

Almost 70% of patients with previously treated RET-fusion–positive non–small cell lung cancer had objective responses to the RET inhibitor selpercatinib (LOXO-292), according to data from the phase I/II LIBRETTO-001 trial presented at the 2019 World Conference on Lung Cancer.

FDA Grants Fast Track Designation to AMG 510 for KRAS G12C+ NSCLC

September 9th 2019

The FDA has granted a fast track designation to AMG 510 for the treatment of patients with KRAS G12C–mutated metastatic non–small cell lung cancer who received prior therapy.

Durvalumab Combo Improves Survival in Frontline Small Cell Lung Cancer

September 9th 2019

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

Bemcentinib/Pembrolizumab Combo Active in Chemo-Refractory NSCLC

September 9th 2019

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

Expert Discusses Novel Agents in Development Targeting EGFR, HER2+ NSCLC

September 9th 2019

Pasi A. Jänne, MD, PhD, discusses 3 studies of novel agents for targeting EGFR-mutant and HER2-positive lung cancers and the next steps in getting the research to cancer clinics.

AMG 510 Highly Active in KRAS+ NSCLC

September 8th 2019

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Approved in Europe for Nonsquamous NSCLC

September 6th 2019

The European Commission has approved atezolizumab for use in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer.

FDA Grants Capmatinib Breakthrough Designation in Frontline METex14-Mutated NSCLC

September 6th 2019

The FDA has granted a breakthrough therapy designation to capmatinib (INC280) as a first-line treatment for patients with MET exon14 skipping—mutated non–small cell lung cancer.

Atezolizumab Combo Approved in Europe for Small Cell Lung Cancer

September 6th 2019

The European Commission has approved atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of adult patients with extensive-stage small cell lung cancer, according to Roche (Genentech) the developer of the PD-L1 inhibitor.

Novel Lung Cancer Therapy: Future Improvements and Challenges

September 6th 2019

MET as a Clinical Target in Lung Cancer

September 6th 2019